Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5
Maxim Group analyst Jason McCarthy initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announces Price Target of $3.5.
Stocks · News reference
MIRA Pharmaceuticals Submits Phase 2a Ketamir‑2 Protocol For CIPN To IRB, Incorporating FDA Feedback And Targeting Q1 2027 Site Initiation
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)
Filed: 2026-09-17 AccNo: 0001493152-26-043051 Size: 241 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?
MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief.